CTOs on the Move


 
ESTECH is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in San Ramon, CA. To find more information about ESTECH, please visit www.estech.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.estech.com
  • 2603 Camino Ramon Ste 100
    San Ramon, CA USA 94583-2100
  • Phone: 925.866.7111

Executives

Name Title Contact Details

Similar Companies

Hortense and Louis Rubin Dialysis Center

Hortense and Louis Rubin Dialysis Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Troy, NY. To find more information about Hortense and Louis Rubin Dialysis Center, please visit www.rubindialysis.org

Valley Behavioral Health

Since 1987, Valley Behavioral Health has provided comprehensive treatment and services for people of all ages who are experiencing serious mental illness, substance use disorders and behavior problems. We believe people are best served in the least restrictive setting where care is tailored to the individual's needs. Families and community partners play an important role in a person's recovery.

Kelly Productions Inc

Kelly Productions Inc is a Bel Air, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rapid Diagnostek

Rapid Diagnostek is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.